JP2008500999A - 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用 - Google Patents

複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用 Download PDF

Info

Publication number
JP2008500999A
JP2008500999A JP2007513941A JP2007513941A JP2008500999A JP 2008500999 A JP2008500999 A JP 2008500999A JP 2007513941 A JP2007513941 A JP 2007513941A JP 2007513941 A JP2007513941 A JP 2007513941A JP 2008500999 A JP2008500999 A JP 2008500999A
Authority
JP
Japan
Prior art keywords
alkyl
alkylcarbonyl
compound
halogen
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007513941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500999A5 (cg-RX-API-DMAC7.html
Inventor
ヘーロルト,ペーター
マー,ロバート
チンケ,ヴィンチェンツォ
シューマッハー,クリストフ
ベーンケ,ディルク
クヴィルムバハ,ミヒャエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Speedel Experimenta AG
Original Assignee
Speedel Experimenta AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta AG filed Critical Speedel Experimenta AG
Publication of JP2008500999A publication Critical patent/JP2008500999A/ja
Publication of JP2008500999A5 publication Critical patent/JP2008500999A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2007513941A 2004-05-28 2005-05-27 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用 Pending JP2008500999A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH9162004 2004-05-28
CH11572004 2004-07-09
PCT/EP2005/052418 WO2005118541A2 (en) 2004-05-28 2005-05-27 Heterocyclic compounds and their use as aldosterone synthase inhibitors

Publications (2)

Publication Number Publication Date
JP2008500999A true JP2008500999A (ja) 2008-01-17
JP2008500999A5 JP2008500999A5 (cg-RX-API-DMAC7.html) 2008-07-10

Family

ID=34993240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513941A Pending JP2008500999A (ja) 2004-05-28 2005-05-27 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用

Country Status (11)

Country Link
US (1) US20080076794A1 (cg-RX-API-DMAC7.html)
EP (1) EP1748986B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008500999A (cg-RX-API-DMAC7.html)
AR (1) AR050251A1 (cg-RX-API-DMAC7.html)
AT (1) ATE490241T1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510412A (cg-RX-API-DMAC7.html)
CA (1) CA2568164A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005025110D1 (cg-RX-API-DMAC7.html)
IL (1) IL179409A0 (cg-RX-API-DMAC7.html)
TW (1) TW200608978A (cg-RX-API-DMAC7.html)
WO (1) WO2005118541A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR049126A1 (es) * 2004-05-28 2006-06-28 Speedel Experimenta Ag Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200804378A (en) * 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
PL2435409T3 (pl) 2009-05-28 2015-01-30 Novartis Ag Podstawione pochodne aminopropionowe jako inhibitory neprylizyny
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
IL324432A (en) 2023-05-24 2026-01-01 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6429376A (en) * 1987-07-08 1989-01-31 Ciba Geigy Ag 1,2-benzoisoxazole and 1,2-benzoisothiazole derivative
JPH0291074A (ja) * 1988-09-02 1990-03-30 Farmitalia Carlo Erba Spa 置換された5,6,7,8‐テトラヒドロイミダゾ[1,5‐a]ピリジン及びその製造方法
JPH02169518A (ja) * 1988-10-26 1990-06-29 Ciba Geigy Ag 二環式イミダゾール化合物
JPH0386880A (ja) * 1989-06-05 1991-04-11 Dai Ichi Seiyaku Co Ltd 縮合トリアジン誘導体及びその中間体
JPH03153686A (ja) * 1989-11-01 1991-07-01 Janssen Pharmaceut Nv (6,7―ジヒドロ―5H―ピロロ[1,2―c]イミダゾリ―5―ル)―および(5,6,7,8―テトラヒドロイミダゾ[1,5―a]ピリジニ―5―ル)置換された1H―ベンゾトリアゾール誘導体
JPH07503242A (ja) * 1992-01-27 1995-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アロマターゼ阻害剤としてのピロロイミダゾリルおよびイミダゾピリジニル置換1h−ベンズイミダゾール誘導体
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0401707T3 (da) * 1989-06-05 1994-10-17 Daiichi Seiyaku Co Heterocyclisk forbindelse, et farmaceutisk lægemiddel og fremgangsmåde til fremstilling af disse
EP1311192A4 (en) * 1999-10-22 2006-03-01 Glaxo Group Ltd -G- (IN VIVO) IMAGING
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6429376A (en) * 1987-07-08 1989-01-31 Ciba Geigy Ag 1,2-benzoisoxazole and 1,2-benzoisothiazole derivative
JPH0291074A (ja) * 1988-09-02 1990-03-30 Farmitalia Carlo Erba Spa 置換された5,6,7,8‐テトラヒドロイミダゾ[1,5‐a]ピリジン及びその製造方法
JPH02169518A (ja) * 1988-10-26 1990-06-29 Ciba Geigy Ag 二環式イミダゾール化合物
JPH0386880A (ja) * 1989-06-05 1991-04-11 Dai Ichi Seiyaku Co Ltd 縮合トリアジン誘導体及びその中間体
JPH03153686A (ja) * 1989-11-01 1991-07-01 Janssen Pharmaceut Nv (6,7―ジヒドロ―5H―ピロロ[1,2―c]イミダゾリ―5―ル)―および(5,6,7,8―テトラヒドロイミダゾ[1,5―a]ピリジニ―5―ル)置換された1H―ベンゾトリアゾール誘導体
JPH07503242A (ja) * 1992-01-27 1995-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アロマターゼ阻害剤としてのピロロイミダゾリルおよびイミダゾピリジニル置換1h−ベンズイミダゾール誘導体
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体

Also Published As

Publication number Publication date
WO2005118541A2 (en) 2005-12-15
BRPI0510412A (pt) 2007-10-23
AR050251A1 (es) 2006-10-11
DE602005025110D1 (de) 2011-01-13
CA2568164A1 (en) 2005-12-15
EP1748986A2 (en) 2007-02-07
TW200608978A (en) 2006-03-16
US20080076794A1 (en) 2008-03-27
ATE490241T1 (de) 2010-12-15
IL179409A0 (en) 2007-05-15
WO2005118541A3 (en) 2006-02-02
EP1748986B1 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
JP5179174B2 (ja) アルドステロンシンターゼ阻害剤としてのテトラヒドロ−イミダゾ[1,5−a]ピリジン誘導体
JP2008500998A (ja) 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用
EP1748986B1 (en) Heterocyclic compounds and their use as aldosterone synthase inhibitors
JP5165558B2 (ja) アルドステロンシンターゼ阻害剤としての複素環スピロ化合物
JP4980417B2 (ja) アルドステロン合成酵素インヒビターとしての縮合イミダゾール誘導体
JP5007299B2 (ja) アルドステロンシンターゼ阻害剤としての複素環スピロ化合物
CN101421279B (zh) 咪唑化合物
JP2008542333A (ja) アルドステロンシンターゼ阻害剤としての縮合イミダゾール誘導体及びその使用
JP5258573B2 (ja) ビス−へテロ環式イミダゾリル化合物
WO2006005726A2 (en) Heterocyclic compounds
JP5350220B2 (ja) スピロ−イミダゾ化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080523

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111108